The Bromodomain: A New Target in Emerging Epigenetic Medicine

Steven G. Smith, Ming Ming Zhou

Research output: Contribution to journalReview articlepeer-review

98 Scopus citations

Abstract

The bromodomain (BrD) is a conserved protein modular domain found in many chromatin- and transcription-associated proteins that has the ability to recognize acetylated lysine residues. This activity allows bromodomains to play a vital role in many acetylation-mediated protein-protein interactions in the cell, ranging from substrate recruitment for histone acetyltransferases (HATs) to aiding in multiple-protein complex assembly for gene transcriptional activation or suppression in chromatin. In recent years, considerable efforts have been made to develop chemical inhibitors of these bromodomains in an effort to probe their cellular functions. Potent and selective inhibitors have been extensively developed for one group of the bromodomain family termed BET proteins that consist of tandem bromodomains followed by an extra terminal domain. Drug developers are actively designing inhibitors of other bromodomains and working to move the most successful inhibitors into the clinic.

Original languageEnglish
Pages (from-to)598-608
Number of pages11
JournalACS Chemical Biology
Volume11
Issue number3
DOIs
StatePublished - 18 Mar 2016

Fingerprint

Dive into the research topics of 'The Bromodomain: A New Target in Emerging Epigenetic Medicine'. Together they form a unique fingerprint.

Cite this